Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$99.27 USD

99.27
4,182,726

+1.56 (1.60%)

Updated May 31, 2024 04:00 PM ET

After-Market: $99.27 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System

by Zacks Equity Research

Axonics' (AXNX) fourth-generation rechargeable Sacral Neuromodulation system will reduce the frequency of patient recharges significantly. The new form factor ensures ease of use.

Ritujay Ghosh headshot

5 Low-Beta Stocks for Safe Returns as Inflation Rises Again

by Ritujay Ghosh

Low-beta stocks like Atmos Energy Corporation (ATO), Balchem Corporation (BCPC), Cardinal Health, Inc. (CAH), Casey's General Stores, Inc. (CASY) and Colgate-Palmolive Company (CL) are a safe bet amid the ongoing market volatility.

Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Philips (PHG) Expands Sonicare Portfolio With Latest Launch

by Zacks Equity Research

Philips (PHG) adds Philips One for Kids toothbrush into its Sonicare family, boosting its Personal Health business.

BD's (BDX) ADC System Favored by New Study for Long-Term Care

by Zacks Equity Research

BD's (BDX) ADC system is likely to result in improvements in clinical workflow, operational efficiency and financial savings in long-term care facilities.

Inari Medical's (NARI) ClotTriever Improves Patient Outcome

by Zacks Equity Research

Inari Medical (NARI) announces two-year interim results from the CLOUT registry, which shows a significant improvement in patient's post-thrombotic syndrome and lower rethrombosis-related events.

Envista (NVST) Faces Macroeconomic Challenges, FX Headwind

by Zacks Equity Research

The challenging macroeconomic conditions are resulting in a significant escalation in Envista's (NVST) costs and expenses.

Inspira Technologies (IINN) Releases Favorable Data on VORTX

by Zacks Equity Research

Inspira Technologies' (IINN) proprietary orbiting oxygenation technology eliminates the need for membrane fibers, thereby reducing pressure differentials and high shear stress.

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.

Bruker (BRKR) Up 20.7% Since Last Earnings: What's Driving It?

by Zacks Equity Research

Investors are upbeat about Bruker (BRKR) led by strong NANO group prospects and strong guidance.

Chemed's (CHE) VITAS Segment Inks New Deal With Covenant Care

by Zacks Equity Research

Chemed's (CHE) VITAS segment is set to acquire the hospice assets of Covenant Care in Florida and Alabama.

UnitedHealth's (UNH) Payment System Disrupted by Cyberattack

by Zacks Equity Research

A cyberattack on UnitedHealth's (UNH) payment management subsidiary, Change Healthcare, last month continues to impact healthcare services, especially cancer treatments, as payment processing remains disrupted.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED), led by growth in the U.S. spine business and progress in the recently merged NuVasive business.

AMN Healthcare (AMN) Expands Capabilities of ShiftWise Flex

by Zacks Equity Research

AMN Healthcare's (AMN) expansion of the capabilities of ShiftWise Flex is likely to enhance internal resource pool management for the healthcare system.

Edwards Lifesciences' (EW) SAPIEN TAVR Study Outcome Favorable

by Zacks Equity Research

Edwards Lifesciences' (EW) recent study provides insights into the actual performance of small Edwards valves and reaffirms the excellent outcomes for patients receiving SAPIEN TAVR.

Philips (PHG), AWS Unite to Scale Digital Pathology Solutions

by Zacks Equity Research

Philips (PHG) collaborates with Amazon Web Services to boost cloud-based pathology solutions. It will enable pathology laboratories to use digital processes to improve analytical capabilities.

PacBio's (PACB) New Panel to Aid Its Clinical Research Solution

by Zacks Equity Research

PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.

Alcon's (ALC) New Launch Strengthens IOL Innovation Leadership

by Zacks Equity Research

Alcon's (ALC) Clareon platform is available in India in two PCIOL technologies, PanOptix and Vivity.

Roche (RHHBY) Launches AI-Based Predictive CGM Accu-Chek

by Zacks Equity Research

Roche (RHHBY) is likely to enter the growing diabetes market with its AI-enabled predictive glucose monitoring system that may revolutionize diabetes management.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Integra LifeSciences (IART) Introduces MicroMatrix Flex

by Zacks Equity Research

Integra LifeSciences' (IART) MicroMatrix Flex has a flexible tip that delivers a flowable version of the Urinary Bladder Matrix (UBM) technology.

Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Orthofix's (OFIX) fourth-quarter earnings and revenues beat their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.

Philips (PHG) Aids Personal Health Business With New Campaign

by Zacks Equity Research

Philips (PHG) launches #ShareTheCare brand positioning campaign for Philips Avent, bolstering the Personal Health segment.

ClearPoint's (CLPT) Prism System Favored by Latest Study

by Zacks Equity Research

ClearPoint's (CLPT) Prism Neuro Laser Therapy System is likely to provide an integrated solution for precise and more efficient laser interstitial thermal therapy.

Here's Why You Should Retain BD (BDX) to Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches raises optimism about the stock.